Chirtel S J, Coutlakis P J, Chambers L L, Lakshman M R
Lipid Research Laboratory, V.A. Medical Center, Washington, D.C. 20422.
J Lab Clin Med. 1989 May;113(5):632-41.
A sensitive, accurate, and reliable method is described for calibrating the rate immunonephelometric assay of rat and human plasma apolipoprotein A (Apo A). Pure Apo A and high-density lipoprotein (HDL) of known Apo A concentration were used in endpoint nephelometry to determine Apo A concentrations of rat and human plasma pools. The endpoint method had coefficients of variation of 7.96% and 4.35% for rat and human plasma pools, respectively. These plasma pools were then used as secondary standards for the rate nephelometric assay. Excellent agreement (+/- 6%) existed between the plasma Apo A values determined by endpoint nephelometry and rate nephelometry. The Apo A concentration of a frozen human plasma pool determined by endpoint nephelometry was 125.2 +/- 9.6 mg/dl. The value of the same pool determined by rate nephelometry over a 1-year period with the Centers for Disease Control WHO lyophilized plasma standard was 125.4 +/- 21.2 mg/dl. Furthermore, it was found that the rat HDL was also a suitable standard in the rate nephelometric assay of Apo A. In contrast, Apo A, purified to homogeneity, showed different reaction kinetics from that of Apo A in the whole plasma and therefore was not a suitable standard in the rate nephelometric assay. We therefore conclude that primary standard Apo A, purified to homogeneity, can be used by endpoint nephelometry to calibrate plasma pools that can then be used as secondary standards in the rate nephelometric determination of rat and human plasma Apo A. The ready applicability of this method in the accurate determination of plasma Apo A under well-defined experimental conditions such as in chronic ethanol-fed rats and in human subjects with normal lipid levels and those with hyperlipidemia is demonstrated.
本文描述了一种灵敏、准确且可靠的方法,用于校准大鼠和人血浆载脂蛋白A(Apo A)的速率免疫比浊法。使用纯Apo A和已知Apo A浓度的高密度脂蛋白(HDL)进行终点比浊法,以测定大鼠和人血浆池的Apo A浓度。终点法对大鼠和人血浆池的变异系数分别为7.96%和4.35%。然后将这些血浆池用作速率比浊法的二级标准品。终点比浊法和速率比浊法测定的血浆Apo A值之间存在极好的一致性(±6%)。通过终点比浊法测定的冷冻人血浆池的Apo A浓度为125.2±9.6mg/dl。使用疾病控制中心世界卫生组织冻干血浆标准品,通过速率比浊法在1年期间测定的同一血浆池的值为125.4±21.2mg/dl。此外,还发现大鼠HDL在Apo A的速率比浊法测定中也是合适的标准品。相比之下,纯化至同质的Apo A与全血浆中的Apo A表现出不同的反应动力学,因此在速率比浊法测定中不是合适的标准品。因此,我们得出结论,纯化至同质的一级标准品Apo A可通过终点比浊法用于校准血浆池,然后这些血浆池可作为大鼠和人血浆Apo A速率比浊法测定的二级标准品。证明了该方法在明确的实验条件下,如在慢性乙醇喂养的大鼠以及血脂正常和高脂血症的人类受试者中准确测定血浆Apo A的适用性。